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London, London SE1 1UL, UKAbstract—Paclitaxel is a ﬁrst-line chemotherapeutic with
the major dose-limiting side eﬀect of painful neuropathy.
Previous preclinical studies indicate mitochondrial
dysfunction and oxidative stress are associated with this
disorder; however no direct assessment of reactive oxygen
species (ROS) levels and antioxidant enzyme activity in
sensory neurons following paclitaxel has been undertaken.
As expected, repeated low doses of systemic paclitaxel in
rats induced long-lasting pain behaviour with a delayed
onset, akin to the clinical scenario. To elucidate the role of
ROS in the development and maintenance of paclitaxel-
induced painful neuropathy, we have assessed ROS and
antioxidant enzyme activity levels in the nociceptive system
in vivo at three key behavioural time-points; prior to pain
onset (day 7), peak pain severity and pain resolution. In
isolated dorsal root ganglia (DRG) neurons, ROS levels were
unchanged following paclitaxel-exposure in vitro or in vivo.
ROS levels were further assessed in DRG and spinal cord
in vivo following intrathecal MitoTrackerRedCM-H2XRos
administration in paclitaxel-/vehicle-treated rats. ROS levels
were increased at day 7, speciﬁcally in non-peptidergic DRG
neurons. In the spinal cord, neuronally-derived ROS was
increased at day 7, yet ROS levels in microglia and astro-
cytes were unaltered. In DRG, CuZnSOD and glutathione
peroxidase (GPx) activity were increased at day 7 and peak
pain time-points, respectively. In peripheral sensory nerves,
CuZnSOD activity was increased at day 7, and at peak pain,
MnSOD, CuZnSOD and GPx activity were increased.
Catalase activity was unaltered in DRG and saphenous
nerves. These data suggest that neuronally-derived
mitochondrial ROS, accompanied with an inadequate
endogenous antioxidant enzyme response, are contributoryhttp://dx.doi.org/10.1016/j.neuroscience.2016.06.050
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INTRODUCTION
Paclitaxel (Taxol) is a taxane-derived chemotherapeutic
and ﬁrst-line treatment for solid tumours. Its primary
anti-cancer action occurs via disruption of the mitotic
spindle and microtubule dynamics causing apoptosis
(Fuchs and Johnson, 1978; Rowinsky et al., 1988;
Jordan et al., 1993). The major dose-limiting side eﬀect
of paclitaxel treatment is painful peripheral neuropathy,
which is predominantly sensory and increases with
cumulative dosing (Postma et al., 1995). Aﬀected patients
typically report bilateral numbness, tingling, spontaneous
pain and evoked pain to mechanical and cold stimuli in the
hands and/or feet (Forsyth et al., 1997; Dougherty et al.,
2004; Boyette-Davis et al., 2013). Paclitaxel-induced
neuropathy can persist for months or years following ces-
sation of paclitaxel (van den Bent et al., 1997; Dougherty
et al., 2004; Boyette-Davis et al., 2013). At present, there
are no treatments to prevent the development of
paclitaxel-induced neuropathy and/or reverse it when
established. Therefore, the emergence of painful
neuropathy during paclitaxel therapy often results in the
discontinuation of otherwise successful chemotherapy,
thus impacting on both the quality of life (Tofthagen,
2010) and survival of cancer patients.
A rat model of paclitaxel-induced painful neuropathy,
using low doses of clinically-formulated paclitaxel,
mimics the scenario of multiple non-consecutive
systemic injections (akin to treatment cycles), evoking
mechanical/cold hypersensitivities, with similar time-
courses to those seen in patients (Flatters and Bennett,
2004, 2006; Fidanboylu et al., 2011; Griﬃths and
Flatters, 2015). Using this model, an extensive electron
microscopy study identiﬁed paclitaxel-induced changes
in the mitochondria of sensory axons in saphenous
nerves which correlated with development and mainte-
nance of paclitaxel-induced pain behaviour (Flatters and
Bennett, 2006).
Several reports have explored the contributory
role of reactive oxygen species (ROS) in vivo to/licenses/by/4.0/).
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ROS scavenging agents. Phenyl-N-tert-butylnitrone
(PBN), a nonspeciﬁc ROS scavenger, inhibited
development and reversed established paclitaxel-
induced pain behaviours (Kim et al., 2010; Fidanboylu
et al., 2011). Peroxynitrite decomposition catalysts have
also been shown to prevent the development and reversed
established paclitaxel-induced mechanical hypersensitiv-
ity (Doyle et al., 2012). Systemic acetyl-L-carnitine (ALC)
administration prevented the development of paclitaxel-
induced mechanical hypersensitivity (Flatters et al.,
2006) and the paclitaxel-evoked increase of atypical mito-
chondria in C-ﬁbres of the saphenous nerve (Jin et al.,
2008). However, there is no direct evidence demonstrating
in vivo paclitaxel treatment increases ROS production
in vivo. In vitro investigations have shown increased
ROS following paclitaxel exposure in isolated rat liver mito-
chondria (Varbiro et al., 2001), human breast (Fawcett
et al., 2005; Alexandre et al., 2007) and bladder
(Ramanathan et al., 2005) cancer cell lines, but whether
paclitaxel can increase ROS in sensory neurons speciﬁ-
cally, in vitro and/or in vivo, remains to be clariﬁed.
Several endogenous antioxidant enzymes work to
control ROS to prevent damage. The superoxide
dismutase (SOD) family consists of three enzymes;
mitochondrial MnSOD, predominately cytoplasmic
CuZnSOD, and extracellular, non-neuronal derived
ECSOD (Okado-Matsumoto and Fridovich, 2001; Zelko
et al., 2002). MnSOD and CuZnSOD rapidly scavenge
and dismutate superoxide, acting as a ﬁrst line of defence
against electron transport chain-derived oxidative stress
(Zelko et al., 2002; Candas and Li, 2014). Other key
facets of the ROS management response are glutathione
peroxidase (GPx) and peroxisome-based catalase. Their
discrete subcellular locations allow rapid, speciﬁc hydro-
gen peroxide management (Weydert and Cullen, 2010).
The activity of endogenous antioxidant enzymes – SOD,
GPx and catalase – likely determine the consequence of
ROS and an upregulation in their activity could indicate
increased ROS.
Given our previous ﬁndings (Flatters and Bennett,
2006; Fidanboylu et al., 2011), here we aim to elucidate
the putative contributory role of ROS in development
and maintenance of paclitaxel-induced painful neuropa-
thy. We sought to determine whether ROS levels chan-
ged in sensory neurons in response to paclitaxel
exposure in vitro or in vivo. We have examined ROS
levels in vivo at key junctions of nociceptive signalling
integration – the dorsal root ganglia (DRG) and spinal
cord – prior to, during, and at the resolution of the
paclitaxel-induced pain behaviour. Furthermore, we have
assessed the activity of the major antioxidant enzymes –
MnSOD, CuZnSOD, GPx & catalase – in peripheral sen-
sory nerves and DRG at these three critical time points.
Therefore, through an extensive series of experiments,
we have addressed where ROS levels are altered in the
nociceptive system and the status of the antioxidant
response at these sites, in correlation to the time-course
of paclitaxel-induced painful neuropathy. Data from these
studies were previously presented in abstract form
(Griﬃths et al., 2012; Duggett et al., 2015).EXPERIMENTAL PROCEDURES
Behavioural assessment and drug administration
Adult male Sprague–Dawley rats (180–220 g; Harlan)
were housed in cages of 3–4 with sawdust bedding and
environmental enrichment materials, in a climate-
controlled environment with a 12 h light/dark cycle
(lights on at 7 am). Food and water were freely
available. All procedures were conducted in strict
accordance with the UK Animals (Scientiﬁc Procedures)
Act, 1986 and the IASP ethical guidelines
(Zimmermann, 1983). The protocol was approved by the
Ethics Review Panel of King’s College London and con-
ducted under the UK Home Oﬃce project license
70/8015. As previously described (Fidanboylu et al.,
2011; Griﬃths and Flatters, 2015), animals were
habituated to the testing environment and mechanical
hypersensitivity was assessed by withdrawal responses
to von Frey ﬁlaments with bending forces of 4g, 8g and
15g. Three baseline measurements were taken prior to
paclitaxel/vehicle administration and mechanical hyper-
sensitivity was measured at 1–3 week intervals until the
paclitaxel-induced pain syndrome resolved. Three critical
time-points of paclitaxel-induced mechanical hypersensi-
tivity were investigated in these studies: day 7 – 24 h after
the last injection of paclitaxel, prior to emergence of
mechanical hypersensitivity; day 23–31 – peak of
mechanical hypersensitivity (von Frey responses
recorded as P2.5-fold higher than baseline responses);
day 173–220 – resolution of mechanical hypersensitivity
(return to individual baseline responses observed on two
separate occasions). Sample sizes were based on the
number of animals used in a given experiment.
The clinical formulation of 6 mg/ml Paclitaxel Solution
for Infusion (Actavis Ltd, Barnstaple, Devon, UK) was
diluted with 0.9% sterile saline (Fresenius Kabi,
Runcorn, Cheshire, UK) to achieve a 2-mg/ml solution.
A vehicle solution of 1:1 cremophor EL and ethanol,
plus 2 mg/ml sodium citrate, replicated the clinical
formulation of paclitaxel. For vehicle administration; one
part vehicle solution was diluted with two parts 0.9%
sterile saline. Animals received intraperitoneal 2 mg/kg
paclitaxel or equivalent volume of vehicle solution on
four alternate days (0, 2, 4, 6), as previously described
(Flatters and Bennett, 2006).Isolation of dorsal root ganglia (DRG) neurons
DRG were dissected bilaterally starting from L6/L5,
proceeding rostrally with 10–14 DRG harvested from
each animal. Further dissection removed the ventral
root, and partially removed the dura mater/dorsal root.
DRG were then transferred to fresh MEM (Sigma,
Gillingham, Dorset, UK) containing 1% penicillin/
streptomycin (Invitrogen, Paisley, Renfrewshire, UK),
2.5 mg/ml collagenase (type IV, Worthington
Biochemicals, Lakewood, New Jersey, USA), and
incubated at 37 C for 3 h. DRG were triturated and
trypsin (0.25 mg/ml) added for 10–20 min at 37 C. A
single-cell suspension was diluted with MEM+ 10%
FBS, 1% P/S, and centrifuged at 1000 rpm for 5 min.
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FBS, 0.1 mg/ml DNase I (Worthington Biochemicals,
Lakewood, New Jersey, USA), pipetted onto a 15%
BSA (Sigma, Gillingham, Dorset, UK) cushion in MEM,
and centrifuged for 10 min at 1000 rpm. The
debris/myelin layer formed at the solution interface was
discarded before removing media to leave a cell pellet.
This was resuspended in MEM +1% P/S, 10% FBS,
0.1% cytosine arabinoside before plating.
In vitro application of ﬂuorescent mitochondrial
probes
In all experiments, dissociated DRG cells were plated onto
poly-D-lysine-coated glass coverslips in humidiﬁed 4-well
plates and kept at 37 C, 5% CO2 overnight. Coverslips
were exposed to 250 ng/ml paclitaxel (prepared from
clinically-formulated 6 mg/ml Paclitaxel with sterile
saline/MEM) or equivalent vehicle solution for 3 h at
37 C, 5% CO2. In separate experiments, DRG neurons
were isolated from paclitaxel-/vehicle-treated rats at day
7 (n= 8 animals/group), peak pain (days 23–31, n= 7
animals/group) and resolution of pain (days 173–194,
n= 7 animals/group).
Two mitochondrial-targeted reduced probes were
used to identify ROS; MitoTracker Red CM-H2XRos
(MTRed; Molecular Probes, Thermo Fisher Scientiﬁc,
M7513, Loughborough, Leicestershire, UK) and
MitoSOXTM Red (MitoSOX; Molecular Probes, Thermo
Fisher Scientiﬁc, M7514, Loughborough, Leicestershire,
UK). MTRed ﬂuoresces following oxidation by all ROS
species, whereas MitoSOX ﬂuorescence is
predominantly via oxidation by superoxide radicals.
MTRed/MitoSOX were reconstituted in 1:1 DMSO &
0.9% sterile saline, followed by further dilution in MEM.
Coverslips were exposed to 5 lM MTRed or 1 lM
MitoSOX for 15 min, at 37 C, 5% CO2, in the dark.
Solutions were removed and coverslips were ﬁxed in
cold 4% PFA for 5 min, rinsed with phosphate-buﬀered
saline (PBS), then dH2O, and mounted onto slides using
Vectashield Antifade Mounting Medium (Vectashield;
Vector Laboratories, Peterborough, Cambridgeshire,
UK). To show co-localisation of MTRed and MitoSOX
probes in mitochondria in these DRG cell preparations,
coverslips were simultaneously exposed to 200 nM
MTGreen and 5 lM MTRed or 1 lM MitoSOX as
described above. Coverslips were then ﬁxed, washed
and mounted onto slides using Vectashield Antifade
Mounting Medium with DAPI (Vectashield + DAPI;
Vector Laboratories, Peterborough, Cambridgeshire, UK).
Coverslips were imaged using a ﬂuorescence
microscope (AxioPlan2; Zeiss, Jena, Germany) with a
Plan NeoFluar 20/0.50 objective lens. For cells
co-labelled with MTGreen, images were taken with a
ﬂuorescence microscope with ApoTome attachment
(AxioPlan2; Zeiss, Jena, Germany) and a Plan
Apochromat 40/0.95 objective lens. Using Adobe
Photoshop CS5 Extended, diameter and ﬂuorescence
intensity of each DRG neuron was measured. DRG
neurons were easily distinguished from non-neuronal
cells due to their greater ﬂuorescence and large,
rounded appearance. DRG neurons were categorisedbased on diameter: small (10–25 lm), medium
(25–50 lm) or large (>50 lm). The number of neurons
measured in each category is indicated in each ﬁgure.
Sample sizes in all analyses are based on the number
of animals used in each experiment. Mean ﬂuorescence
intensity of small, medium and large neurons was
determined for each animal, then mean ± SEM
calculated for the neuronal size category, from each
group of animals used.
MTRed ﬂuorescence intensity of DRG neurons from
paclitaxel-treated animals was expressed as a
percentage of the MTRed ﬂuorescence intensity of DRG
neurons from vehicle-treated animals within each
harvest (consisting of one vehicle-treated and one
paclitaxel-treated rat; n= 7–8 animals per group). This
within-experiment normalisation controlled for variability
between diﬀerent lot numbers of MTRed/MitoSOX and
microscope bulbs used during the experiments.
Therefore, paired data analysis was used for these
experiments. All image analysis was performed under
blind conditions.In vivo application of ﬂuorescent mitochondrial
probes
Pilot studies determined that in vivo application of these
probes to peripheral sensory nerves via epineural
injection did not allow suﬃcient spread and permeation
for adequate analysis of ROS in peripheral nerves.
Under isoﬂurane anaesthesia, paclitaxel-/vehicle-treated
rats received intrathecal (IT) injections of 90 ll of
100 lM MTRed (reconstituted with 1:1 DMSO and 0.9%
sterile saline) or equivalent vehicle. Entrance to the
intrathecal space was identiﬁed by tail movement. Pilot
studies using MitoTracker Red CMXRos (Molecular
Probes, Thermo Fisher Scientiﬁc, Loughborough,
Leicestershire, UK) a non-reduced purple-coloured
probe, determined optimal injection site (between L5/L6
vertebrae) and volume required to ensure suﬃcient
spread within the CSF to L4/L5 spinal cord. Five to
six hours following IT injections, rats were overdosed
with pentobarbital and transcardially perfused with 0.9%
saline containing heparin, followed by cold 4% PFA.
Vertebral columns were removed and post-ﬁxed in 4%
PFA overnight at 4 C. L4/L5 DRG/spinal cord were
dissected and immersed in 30% sucrose solution, at
4 C for 3–5 days. Tissues were then embedded in OCT
and stored at 80 C until cryosectioning.In vivo ROS levels in DRG neurons
Sixteen micrometers sections of L4/L5 DRG were cut
onto slides and coverslipped using Vectashield + DAPI.
Mosaix montages of DRG sections were created using
a ﬂuorescent microscope (AxioPlan 2; Zeiss, Jena,
Germany) with a Plan Apochromat 20/0.75 objective
lens and Texas Red/UV ﬁlters, for MTRed/DAPI-stained
nuclei, respectively. The same exposure time for Texas
Red ﬁlter was used for all images. Neuronal cell bodies
with a round, central nucleus were selected using
AxioVision LE software (v.4.8) to measure ﬂuorescence
intensity and diameter. Neuronal cell bodies were
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(23–32 lm) or large (>32 lm). The mean MTRed
ﬂuorescence of small, medium and large neurons was
determined for individual animals (from three
non-consecutive DRG sections per animal). The
mean ± SEM MTRed ﬂuorescence was calculated for
each neuronal category for paclitaxel-/vehicle-treated
rats at each time point (n= 6 animals/group). Any auto-
ﬂuorescence of DRG neurons (using DRG sections
following vehicle IT injections) could not be visualised
with the chosen exposure time and was concluded to be
minimal. Furthermore, analysis of spinal cord sections
(see below) from rats that received vehicle IT injections,
showed no diﬀerence in autoﬂuorescence between
paclitaxel-/vehicle-treated rats. All analyses were
performed under blind conditions.
Sixteen micrometers L4/5 DRG sections were blocked
for one hour at RT in PBS containing 3% normal goat
serum (NGS), 0.3%Triton-X-100, 0.01% sodium azide.
Calcitonin gene-related peptide (CGRP) or isolectin-B4
(IB4) were used to detect peptidergic or non-peptidergic
neurons, respectively. DRG sections were incubated at
4 C overnight in the dark, with mouse anti-CGRP
(1:2000; Sigma, C7113, Gillingham, Dorset, UK) or IB4
(1:100; Sigma, L3759, Gillingham, Dorset, UK), in PBS
containing 0.1% Triton-X-100 (PBS-T). Following three
10-min PBS washes, sections were exposed to goat
anti-mouse FITC (for CGRP, 1:400; Jackson
ImmunoResearch Laboratories, West Grove,
Pennsylvania, USA) or ExAvidin conjugated with FITC
(for IB4, 1:400; Stratech, Newmarket, Suﬀolk, UK) in
PBS-T, for 90 min at RT, in the dark. Sections had three
10-min PBS washes and then coverslipped with
Vectashield + DAPI. A three-channel Mosaix montage
of the entire DRG section was taken using a Plan
Apochromat 20/0.75 objective lens and Texas
Red/FITC/UV ﬁlters for MTRed/CGRP or IB4/DAPI-
stained nuclei, respectively. The same exposure time for
Texas Red ﬁlter was used for all images. CGRP-/
IB4-positive neurons were selected to measure MTRed
ﬂuorescence and diameter, with mean MTRed
ﬂuorescence determined for each animal (from
measurements on one CGRP-labelled section and 1–2
non-consecutive IB4-labelled sections per animal). The
mean ± SEM MTRed ﬂuorescence was calculated for
each neuronal category, for paclitaxel-/vehicle-treated
rats at each time point (n= 5–6 animals/group). All
analyses were performed under blind conditions.
In vivo ROS levels in the spinal cord
Ten micrometers sections of L4/L5 spinal cord were cut,
mounted and coverslipped using Vectashield. Images of
the dorsal horn were taken using a ﬂuorescent
microscope with Plan NeoFluar 20/0.50 objective lens
and Texas Red ﬁlter. One image was taken per section
and the same exposure time used for all images. Using
AxioVision, an area (132,521.38 lm2) of laminae I-III
was selected to measure the mean ﬂuorescence
intensity. Measurements on sections from rats that
received IT vehicle (DMSO & saline) injections showed
similar average background-/auto-ﬂuorescence betweenpaclitaxel- & vehicle-treated rats. Thus, an average
background ﬂuorescence value was calculated at each
time point and subtracted from the MTRed ﬂuorescence
measured in each MTRed section at that time point.
The average MTRed ﬂuorescence was calculated for
each animal from four to nine non-consecutive sections
(two rats at pain resolution two sections/animal
analysed). n= 6–10 for paclitaxel-/vehicle-treated rats
at each time-point. All analyses were performed under
blind conditions.
ROS levels in spinal neurons, microglia and astrocytes
were examined in paclitaxel-/vehicle-treated rats at day 7.
10 lm spinal cord sections were blocked for 1 h at RT in
PBS containing 3% NGS, 0.3% Triton-X-100, 0.01%
sodium azide. DRG sections were incubated with NeuN
(neuronal marker, 1:100 clone-A60 Millipore, MAB377,
Watford, Hertfordshire, UK); ionized calcium binding
adaptor molecule-1 (IBA-1, microglia marker, 1:1000
WAKO, 019-19741); or glial ﬁbrillary acidic protein
(GFAP, astrocyte marker, 1:5000 Millipore, MAB360,
Watford, Hertfordshire, UK), in PBS-T, at 4 C overnight
in the dark. Following three 10-min PBS washes,
sections were exposed to 1:400 goat anti-mouse or
1:400 goat anti-rabbit FITC secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grove,
Pennsylvania, USA) in PBS-T for 90 min at RT in the
dark. Finally, sections had three 10-min PBS washes and
coverslipped with Vectashield. A two-channel Mosaix
montage of laminae I–III of each section was taken using
a Plan Apochromat 20/0.75 objective lens and Texas
Red/FITC ﬁlters for MTRed/NeuN;IBA-1;GFAP,
respectively. Exposure times were kept consistent
across slides.
For neuronal analysis; NeuN-positive cell bodies were
selected in laminae I–III using AxioVision and MTRed
ﬂuorescence measured. The mean neuronal MTRed
ﬂuorescence was calculated for each animal from three
to seven sections; n= 5–7 rats/group. A total of 4795
and 5474 neurons were analysed from vehicle- and
paclitaxel-treated rats, respectively. For microglial
analysis; using AxioVision, an area (132,521.38 lm2) of
laminae I–III was selected and MTRed ﬂuorescence in
IBA-1-positive cell bodies within this area measured.
The mean microglial MTRed ﬂuorescence was
calculated for each animal from four to six sections;
n= 4 rats/group. For astrocytic analysis: using
Axiovision, an area (132,521.38 lm2) of laminae I–III
was selected. Due to the density/morphology of
astrocytes, individual astrocytic cell bodies could not be
identiﬁed. ImageJ (NIH) plugin, Colocalization Finder,
was used to highlight pixels labelled with both MTRed
and GFAP, giving a percentage of co-staining. All
analyses were performed under blind conditions.
In-gel activity assays of endogenous antioxidant
enzymes
L4/5 DRG and saphenous nerves were harvested from
vehicle- and paclitaxel-treated animals at the three
time-points and ﬂash frozen. Tissue was prepared as
described (Weydert and Cullen, 2010) and methodology
for in-gel activity assays was based on the methods
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Weydert and Cullen, 2010). In brief, 12% or 8% 1.5 mm
separating acrylamide gels were prepared, and run for
1 h at 4 C using pre-electrophoresis buﬀer (190 mM
Tris-Base, 1 mM disodium EDTA, pH 8.8). Samples were
prepared 1:1 with loading buﬀer (250 mM Tris, 4 mM
EDTA, 50% glycerol, 0.2% bromophenol blue).DRG
(100mg) protein was used for SOD gels. In all other
instances, 50 lg protein was used. Following sample
loading, gels were run for three hours at 4 C in
pre-electrophoresis buﬀer. Gels were run for approx. 4 h
at 4 C in electrophoresis buﬀer (50 mM Tris-Base,
0.3 M glycine, 2 mM disodium EDTA, pH 8.3). Paclitaxel
and vehicle samples from the same time point were run
on the same gel. After staining, gels were thoroughly
washed in dH2O and scanned using an Epson V370 scan-
ner. Gels stained for MnSOD or total SOD (two gels run
for each time point) as previously described (Weydert
and Cullen, 2010). Gels stained for GPx or catalase as
outlined (Woodbury et al., 1971; Sun et al., 1988;
Weydert and Cullen, 2010). Staining techniques produced
variable colour intensities; however this was controlled by
running all vehicle and paclitaxel samples within the same
gel. All gels were scanned as black and white images,
bands were then selected and analysed in ImageJ. Band
densities were normalised to adjacent background areas,
with activity normalised to total protein loaded per well.
n= 3–6 paclitaxel-/vehicle-treated rats per time-point.
All statistical analysis was conducted on raw data (not
percentages) using GraphPad Prism 6 or GraphPad
InStat 3 for Windows. Speciﬁc tests used are as
indicated in ﬁgure legends. Statistical signiﬁcance was
accepted at p< 0.05. No further distinction was made
when p< 0.01 or p< 0.001 and is denoted on ﬁgures
as p< 0.05.RESULTS
We have consistently found that four systemic low-dose
(2 mg/kg) injections of paclitaxel administered on days
0, 2, 4 & 6, evokes mechanical hypersensitivity
with a gradual onset. Paclitaxel-induced mechanical
hypersensitivity takes several weeks to reach its peak
(approx. day 26), remains elevated for a few months
and resolves approximately 6 months following the initial
paclitaxel injection. In these studies, we examined
tissues at three key time-points within this time-course;
(1) day 7 – approx. 24 h after the last paclitaxel
administration, prior to the onset of pain behaviour; (2)
day 23–31 – peak of paclitaxel-induced pain behaviour;
(3) day 173–220 – resolution of paclitaxel-induced pain
behaviour. The day of harvest for each rat was dictated
by the behavioural phenotype compared to individual
baseline responses. Pain resolution was variable within
cohorts. Fig. 1 illustrates the pain phenotype present
prior to tissue harvesting for these ex vivo studies. As
expected, we observed a P2.5-fold signiﬁcant increase
in paw withdrawal responses to von Frey 4g, 8g and
15g stimulation at the peak of paclitaxel-induced
mechanical hypersensitivity. In individual cohorts of
animals, signiﬁcant diﬀerences in mechanicalhypersensitivity were not seen between paclitaxel- and
vehicle-treated rats at day 7 and resolution of pain time-
points. However, when these data were collated, small
(less than one withdrawal) but statistically signiﬁcant
increases in responses to von Frey 8g at pain resolution
(Fig. 1B) and to von Frey 15g at day 7 (Fig. 1C) were
seen in paclitaxel-treated rats. It is highly likely that
statistical signiﬁcance observed at these time points is
due to the high n numbers following data collation, day
7 – n= 108–114, pain resolution – n= 30, rather than
a biological eﬀect.
Atypical mitochondria were previously observed in
both peripheral sensory nerves and DRG of rats prior to
and during paclitaxel-induced pain (Flatters and
Bennett, 2006; Jin et al., 2008; Barriere et al., 2012). As
mitochondria are a major source of ROS, we examined
ROS levels in isolated DRG neurons from paclitaxel-
and vehicle-treated rats at day 7, peak pain and pain res-
olution, using MTRed and MitoSOX reduced probes.
There was no signiﬁcant change in the levels of total
ROS (Fig. 2A) or superoxide (Fig. 2D) in small, medium
or large DRG neurons from paclitaxel-treated rats com-
pared to size-matched DRG neurons from vehicle-
treated rats at any time-point. In separate experiments,
in vitro paclitaxel exposure (250 ng/ml – previously shown
to induce mitochondrial dysfunction (Melli et al., 2008))
did not signiﬁcantly alter total ROS or superoxide levels
in isolated naive DRG neurons compared to controls (data
not shown).
As ROS levels were unaltered, we conﬁrmed our
experimental approach with additional experiments.
Firstly, we conﬁrmed MTRed and MitoSOX are entering
mitochondria under our experimental conditions, as our
primary DRG cultures co-labelled with either probe in
combination with MitoTracker Green, showed clear
co-localisation of ﬂuorescence (Fig. 2C, F). Secondly,
additional experiments using 500 nM MTRed also
showed no signiﬁcant diﬀerence in MTRed ﬂuorescence
of DRG neurons from paclitaxel-treated rats compared
to those of vehicle-treated rats at day 7. The mean
ﬂuorescence of DRG neurons with 500 nM MTRed from
paclitaxel-treated rats expressed as a percentage of
mean ﬂuorescence of DRG neurons from vehicle-
treated rats was 103.9%, 106.7% and 93.6%, for small,
medium and large neurons, respectively (n= 5 animals
per group). This indicates that the lack of diﬀerence in
DRG ROS levels between paclitaxel- and vehicle-
treated rats is not due to saturation of the probe at
5 lM. These data suggested that the essential
axotomy/enzymatic processing required to isolate DRG
neurons, elevated ROS levels and thereby masked any
alteration in ROS levels from a direct result of paclitaxel
treatment in vivo.
To examine ROS levels in situ during the
time-course of paclitaxel-induced painful neuropathy,
paclitaxel-/vehicle-treated rats received intrathecal
injections of MTRed/vehicle in vivo. DRG and spinal
cord were then analysed to determine ROS levels in
neuronal/cellular populations. Small increases in ROS
levels were seen in small and medium neurons at peak
pain (Fig. 3B), but were not statistically signiﬁcant.
Fig. 1. Time course of paclitaxel-induced mechanical hypersensitivity. Graphs show the mean ± SEM of the number of withdrawal responses to
(A) 4g, (B) 8g and (C) 15g von Frey ﬁlaments at; baseline, day 7, peak pain (day 23–31) and pain resolution (day 173–220), following paclitaxel/
vehicle administration at days 0, 2, 4 and 6. *p< 0.05, two-tailed multiple comparison unpaired t-tests with Holm-Sidak correction. Day 7 n= 108
vehicle, n= 114 paclitaxel; peak pain n= 73 vehicle, n= 75 paclitaxel; resolution n= 30 vehicle, n= 30 paclitaxel. NB: These data are compiled
from several cohorts of animals used to generate tissues for these studies. Data from each individual cohort show no signiﬁcant diﬀerence in
mechanical hypersensitivity, between vehicle and paclitaxel-treated animals, at day 7 and pain resolution.
Fig. 2. Eﬀect of in vivo paclitaxel on total ROS and superoxide production in isolated DRG neurons. (A) The mean ± SEM of MTRed ﬂuorescence
intensity in small, medium and large isolated DRG neurons from paclitaxel-/vehicle-treated rats at day 7, peak pain (day 23–31) and pain resolution
(day 173–194), n= 7–8 animals per treatment group. Neuronal categories were based on cell body size; small (10–25 lm), medium (25–50 lm)
and large (>50 lm). Numbers in brackets indicate total number of neurons analysed in each category from paclitaxel- and vehicle-treated rats
combined. Dotted line indicates the ﬂuorescence of the vehicle-control group set as 100%. (B) Representative image of MTRed staining in an
isolated DRG preparation. (C) MTRed colocalisation in non-neuronal DRG cells; DAPI stained nuclei are shown in blue, MitoTracker Red and
MitoTracker Green are shown in red and green, respectively. Scale bar = 10 lm. (D) The mean ± SEM of MitoSOX ﬂuorescence intensity of
intensity in small, medium and large isolated DRG neurons from paclitaxel-/vehicle-treated rats at day 7, peak pain (day 24–31) and pain resolution
(day 173–194), n= 7–8 per treatment group. Numbers in brackets indicate total number of neurons analysed in each category from paclitaxel- and
vehicle-treated rats combined. Dotted line indicates the ﬂuorescence of the vehicle-control group set as 100%. (E) Representative image of
MitoSOX staining in an isolated DRG preparation. (F) MitoSOX Red colocalisation in non-neuronal DRG cells; DAPI stained nuclei are shown in
blue, MitoSOX Red and MitoTracker Green are shown in red and green, respectively. Scale bar = 10 lm.
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DRG neurons in vivo during the paclitaxel-induced pain
time-course (Fig. 3). However, trends for altered levels
of ROS production in DRG neurons led us to investigate
whether speciﬁc subpopulations of neurons had altered
ROS levels. There was no signiﬁcant diﬀerence in ROS
levels of peptidergic (CGRP+) neurons in paclitaxel-
treated rats, compared to those in vehicle-treated rats,
at day 7 and peak pain (data not shown). However, at
pain resolution, ROS levels were signiﬁcantly decreasedin small peptidergic neurons of paclitaxel-treated rats
compared to those in vehicle-treated rats (data not
shown). Loss of peptidergic neurons is unlikely as the
proportion of CGRP+ neurons is similar in paclitaxel-
and vehicle-treated rats at all time-points (data not
shown). In comparison, ROS levels were increased in
IB4+ neurons in paclitaxel-treated rats at day 7 and
peak pain compared to vehicle-treated. At day 7,
signiﬁcant increases in ROS levels in both small
(122%) and medium-sized DRG neurons (110%) in
Fig. 3. In vivo ROS levels in DRG neurons during the time-course of paclitaxel-induced painful neuropathy. (A–C) The mean ± SEM of MTRed
ﬂuorescence intensity of small, medium and large DRG neurons in paclitaxel- and vehicle- treated rats in vivo at (A) day 7, (B) peak pain – day
27–30 and (C) pain resolution – day 195–220. Neuronal categories were based on cell body size; small (10–23 lm), medium (23–32 lm) and large
(>32 lm). Numbers in brackets indicate total number of neurons counted in each category, n= 6 animals per treatment group, per time point.
(D–F) Example images of cut DRG from each treatment group; (D) day 7, (E) peak pain and (F) pain resolution. White boxed areas are highlighted
to show DAPI, MTRed and merged image channels. Scale bar = 50 lm. Areas of intense MTRed staining are due to proximity of tissue to
intrathecal injection site and were avoided during analysis.
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pain, ROS levels were increased by 74% in small
neurons and 57% in medium neurons, but these
increases were not statistically signiﬁcant (Fig. 4B). At
pain resolution, ROS levels were unaltered in
IB4+ neurons of paclitaxel-treated rats, compared to
vehicle-treated rats (Fig. 4C). Gain of non-peptidergic
neurons is unlikely as the proportion of IB4+ neurons is
similar in paclitaxel- and vehicle-treated rats at all
time-points (data not shown).
Fig. 5 shows in vivo ROS levels in laminae I–III of the
spinal cord during the time-course of paclitaxel-induced
painful neuropathy, in paclitaxel-/vehicle-treated rats at
day 7, peak pain and pain resolution time-points.
Compared to vehicle-treated rats, spinal ROS levels
were only increased at day 7, although this increase
was not statistically signiﬁcant (Fig. 5A, B). Further
analysis examined if ROS levels at day 7 were
increased in speciﬁc cellular subpopulations within
laminae I–III in paclitaxel-treated rats. ROS levels within
NeuN-positive cell bodies were signiﬁcantly increasedby 23% in paclitaxel-treated rats compared to vehicle-
treated rats (Fig. 5C). In contrast, there was no
signiﬁcant diﬀerence in ROS levels of spinal microglia
and GFAP ﬂuorescence had zero percent co-localisation
with MTRed ﬂuorescence in paclitaxel-/vehicle-treated
rats at day 7 (data not shown).
After determining in vivo paclitaxel exposure
increased ROS levels in DRG and spinal neurons; we
investigated the activity of antioxidant enzyme activity
during the time course of paclitaxel-induced pain in
DRG and saphenous nerves. We measured activity of
two subtypes of SOD: manganese superoxide
dismutase (MnSOD), and copper zinc superoxide
dismutase (CuZnSOD) and observed the expected
approximate ratio of 3:1 (MnSOD:CuZnSOD) (Nedeva
et al., 2004) in both DRG and saphenous nerves
from paclitaxel-/vehicle-treated rats throughout the
time-course. There was no signiﬁcant diﬀerence in
MnSOD activity between paclitaxel- and vehicle-treated
rats in the DRG at any time-point (Fig. 6A). In compar-
ison, there was a signiﬁcant 40% increase in CuZnSOD
Fig. 4. In vivo ROS levels in IB4+ DRG neurons during the time-course of paclitaxel-induced painful neuropathy. (A–C) The mean ± SEM of
MTRed ﬂuorescence intensity of small and medium IB4+ DRG neurons in paclitaxel- and vehicle-treated rats in vivo at (A) day 7, (B) peak pain –
day 27–30 and (C) pain resolution – day 195–220. Neuronal categories were based on cell body size; small (10–23 lm) and medium (23–32 lm).
Numbers in brackets indicate total number of neurons counted in each category, n= 5–6 animals per treatment group, per time point. *p< 0.05
unpaired, one-tailed t-tests. (D–F) Example images of cut DRG from each treatment group; (D) day 7, (E) peak pain and (F) pain resolution. White
boxed areas are highlighted to show DAPI, IB4+, MTRed and merged image channels. Scale bar = 50 lm. Areas of intense MTRed staining are
due to proximity of tissue to intrathecal injection site and were avoided during analysis.
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compared to DRG from vehicle-treated rats (Fig. 6B).
CuZnSOD activity in the DRG was unaltered in paclitaxel-
treated rats at peak pain and pain resolution time-points.
In the saphenous nerve at day 7, there was no change in
MnSOD activity (Fig. 6C); however there was a signiﬁcant
33% increase in CuZnSOD activity in paclitaxel-treated
rats compared to vehicle-treated rats (Fig. 6D). By peak
pain, activities of MnSOD and CuZnSOD in the saphenous
nerve were both signiﬁcantly increased, 76% and 36%
respectively, in paclitaxel-treated rats, compared to
vehicle-treated rats (Fig. 6C, D). At pain resolution,
MnSOD and CuZnSOD activity were unaltered in
saphenous nerves of paclitaxel-treated rats (Fig. 6C, D).
Fig. 7 shows the activity of GPx and catalase in DRG
and saphenous nerves during the time-course ofpaclitaxel-induced painful neuropathy. In the DRG, there
was a signiﬁcant 36% increase in GPx activity in
paclitaxel-treated rats at the peak of paclitaxel-induced
pain, but no change at day 7 and pain resolution,
compared to concurrent vehicle-treated groups
(Fig. 7A). Similarly, in saphenous nerves, there was a
signiﬁcant 51% increase in GPx activity in paclitaxel-
treated rats at the peak of paclitaxel-induced pain
compared to the concurrent vehicle-treated group
(Fig. 7C). There was a 35% increase in GPx activity at
day 7 in saphenous nerves from paclitaxel-treated rats,
but this was not statistically signiﬁcant. At pain
resolution, there was a signiﬁcant 34% decrease in GPx
activity in saphenous nerves from paclitaxel-treated rats
compared to vehicle-treated rats (Fig. 7C). Catalase
activity was not signiﬁcantly altered in DRG or
Fig. 5. In vivo ROS levels in the superﬁcial dorsal horn of the spinal
cord during the time-course of paclitaxel-induced painful neuropathy.
(A) Example images of superﬁcial dorsal horn in sections of L4/5
spinal cord, following intrathecal injection of MTRed. Scale
bar = 50 lm. (B) The mean ± SEM of MTRed ﬂuorescence intensity
in laminae I–III of L4/5 spinal cord in paclitaxel-treated animals,
expressed as a percentage of vehicle-treated controls at day 7, peak
pain (day 27–30) and pain resolution (day 195–220). n= 6–9
animals per treatment group, per time-point. (C) The mean ± SEM
of MTRed ﬂuorescence intensity of NeuN positive neurons in the
dorsal horn of vehicle- and paclitaxel-treated rats at day 7. *p< 0.05
unpaired, one-tailed t-test, n= 5–7 animals per group. No signiﬁcant
diﬀerence in ROS levels of spinal microglia or astrocytes in paclitaxel-
treated rats compared to vehicle-treated rats was evident at day 7,
n= 4 animals per group (data not shown).
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and peak pain time-points (Fig. 7B, D), therefore was
not assessed at pain resolution.DISCUSSION
Our previous preclinical studies demonstrated that
paclitaxel-induced painful neuropathy is associated with
increased atypical mitochondria in sensory axons
(Flatters and Bennett, 2006). Furthermore, pharmacolog-
ical scavenging of ROS inhibited development and main-
tenance of the paclitaxel-induced pain syndrome in vivo
(Fidanboylu et al., 2011). Here, for the ﬁrst time, we have
directly investigated the eﬀect of paclitaxel on ROS levels
in sensory neurons in vitro and in vivo. Moreover, these
studies have assessed levels of ROS and antioxidant
enzyme activity in the nociceptive system, prior to (day
7), during (peak pain), and at resolution of paclitaxel-
induced painful neuropathy. In vitro exposure of naive
DRG neurons to paclitaxel did not alter mitochondrial-
derived ROS or mitochondrial superoxide levels. The con-
centration of paclitaxel (250 ng/ml) and exposure time
(3 h) used, were the same as a previous study reporting
mitochondrial dysfunction in isolated DRG neurons follow-
ing in vitro paclitaxel exposure (Melli et al., 2008). DRG
neurons isolated from paclitaxel-treated rats prior to, dur-
ing and at resolution of paclitaxel-induced pain, did not
show any change in mitochondrial ROS or superoxide
levels compared to DRG neurons from vehicle-treated
rats. This was unexpected, given previous evidence of
mitochondrial dysfunction in DRG neurons following
in vivo paclitaxel administration (Barriere et al., 2012).
We suggest the reason for unaltered ROS/superoxide
levels in isolated DRG neurons observed here, is due to
the essential axotomy and enzymatic dissociation of
DRG neurons, elevating ROS levels to such an extent
that paclitaxel-induced changes in ROS are not detect-
able in this experimental setting.
Following intrathecal administration of reduced ROS
probe MTRed, in vivo ROS levels both within DRG
neurons and the spinal cord could be quantiﬁed in situ.
In small and medium DRG neurons, increased ROS
levels were indicated at day 7 and peak pain
time-points, but these increases were not statistically
signiﬁcant when examining entire neuronal populations
categorised by cell diameter only. However, when
subpopulations of nociceptive neurons were identiﬁed
immunohistochemically and analysed separately;
clear diﬀerential eﬀects were observed between
paclitaxel-/vehicle-treated rats at the three time-points of
interest. At day 7, there was more than a twofold
increase in ROS levels in non-peptidergic IB4+ neurons
from paclitaxel-treated rats whereas ROS remained
unaltered in peptidergic CGRP+ neurons. At peak pain,
ROS was increased in IB4+ neurons from paclitaxel-
treated rats whereas ROS levels were unaltered in
peptidergic CGRP+ neurons. At pain resolution, ROS
levels in IB4+ neurons did not change, but were
reduced in peptidergic CGRP+ neurons from paclitaxel-
treated rats. Recently, evidence has shown paclitaxel
increases MAPK levels diﬀerentially in CGRP+ neurons
compared to IB4+ neurons during paclitaxel-induced
pain (Li et al., 2015). Our data suggest that paclitaxel
preferentially evokes ROS in non-peptidergic neurons
prior to the pain syndrome, which persists in this neuronal
subpopulation to peak pain severity, but resolves when
Fig. 6. Superoxide dismutase activity in the DRG and saphenous nerve during the time-course of paclitaxel-induced painful neuropathy. MnSOD
activity in (A) DRG and (C) saphenous nerves of paclitaxel- and vehicle-treated rats at day 7, peak pain (day 28) and pain resolution (day 182–218),
n= 4–6 animals per group, *p< 0.05 unpaired, two-tailed t-tests. CuZnSOD activity in (B) DRG and (D) saphenous nerves of paclitaxel- and
vehicle-treated rats at day 7, peak pain (day 28) and pain resolution (day 182–218), n= 4–6 animals per group, *p< 0.05 unpaired, two-tailed
t-test. Adjacent panels display scans of activity gels used in analysis, which show signiﬁcantly altered activity between groups. Black line on peak
pain gel due to small tear.
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IB4+ neurons speciﬁcally contributes to development of
paclitaxel-induced pain and perhaps, to a lesser extent,
the maintenance of the pain syndrome. Ablation of the
central terminals of IB4+ primary aﬀerents following
intrathecal IB4-saporin markedly inhibited the develop-
ment of oxaliplatin-induced pain (Joseph et al., 2008). In
addition, both paclitaxel- and oxaliplatin-induced pain
behaviours were inhibited by antioxidants (Flatters et al.,
2006; Joseph et al., 2008; Fidanboylu et al., 2011).
Collectively these data suggest that paclitaxel- and
oxaliplatin-induced painful neuropathy may share a
similar ROS driven, IB4+ neuron-dependent causal
mechanism. In addition, paclitaxel-induced mechanical
hypersensitivity was attenuated when TRPA1 channel
activity was blocked through pharmacological antagonism
(Chen et al., 2011) or genetic manipulation (Materazziet al., 2012). TRPA1 channels are a known neuronal
ROS sensor (Andersson et al., 2008) and are
predominantly expressed on IB4+ DRG neurons
(Barabas et al., 2012). Therefore, the preferential
elevation of ROS in IB4+ neurons described here could
suggest a direct mechanism of TRPA1 channel activity
contributing to paclitaxel-induced pain. However, further
experiments are required to directly assess this potential
mechanism. In the superﬁcial dorsal horn of the spinal
cord, in vivo ROS levels were elevated at day 7 only, prior
to the emergence of paclitaxel-induced pain. Further
analysis on spinal cellular subpopulations at day 7
identiﬁed ROS was signiﬁcantly increased in neurons,
but unaﬀected in microglia and astrocytes, indicating
that neuronal-derived ROS in the spinal cord contributes
to the development of paclitaxel-induced painful
neuropathy.
Fig. 7. Glutathione peroxidase (GPx) and catalase activity in the DRG and saphenous nerve during the time-course of paclitaxel-induced painful
neuropathy. GPx activity in (A) DRG and (C) saphenous nerves of paclitaxel- and vehicle-treated rats at day 7, peak pain (day 28) and pain
resolution (day 182–218), n= 4–6 animals per group. (B) Catalase activity in the DRG of paclitaxel- and vehicle-treated rats at day 7 and peak pain
(day 28), n= 3–5 animals per group. (D) Catalase activity in saphenous nerves of paclitaxel- and vehicle-treated rats at day 7 and peak pain (day
28), n= 5 animals per group. *p< 0.05 unpaired, two-tailed t-tests. Adjacent panels display scans of activity gels used in analysis, which show
signiﬁcantly altered activity between groups.
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following systemic administration (Lesser et al., 1995;
Cavaletti et al., 2000; Xiao et al., 2011). Paclitaxel was
present in liver, but not nervous tissues (spinal cord,
DRG, sciatic nerve, brain), 2 h following a single adminis-
tration of [3H]-paclitaxel (Lesser et al., 1995). In compar-
ison, 24 h following repeated systemic administration
(cumulative dose of 25 mg/kg paclitaxel), high levels were
found in the DRG (Cavaletti et al., 2000) and smaller
levels at other sites: sciatic nerveP liver > spinal
cord > brain & plasma. At day 7, using the same dosing
regimen as here (cumulative dose of 8 mg/kg paclitaxel),
high levels were found in liver and DRG, with smaller
levels at other sites: ventral root > dorsal root > sciatic
nerve > spinal cord > brain & plasma (Xiao et al.,
2011). Paclitaxel was only present in the DRG and liverat day 16, 10 days following the last 2 mg/kg dose of pacli-
taxel (Xiao et al., 2011). In relation to our data, these
studies suggest that increased ROS levels observed at
day 7 in DRG and spinal cord could be attributed to direct
action of paclitaxel at these sites; perhaps via binding to
b-tubulin associated with voltage-dependent anion
channel (VDAC) subunits found on the mitochondrial
membrane (Carre et al., 2002; Kidd et al., 2002). The per-
sistence of paclitaxel in the DRG, albeit at much lower
levels, may also be responsible for smaller elevation in
ROS seen at the peak pain time point.
Collectively, distribution studies suggest that the
majority of the neurotoxic damage caused by paclitaxel
is directed at the DRG and peripheral sensory nerves.
The net eﬀect of paclitaxel-induced ROS, and its
causality to pain, is likely to be somewhat reliant on how
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mammalian cells, mitochondria are not the only source of
ROS; peroxisomes, endoplasmic reticulum, cytoplasm
and the extracellular space are all sites at which ROS is
produced (see (Brown and Borutaite, 2012)). Here, we
analysed CuZnSOD/MnSOD and GPx/catalase activity,
to appreciate the management of superoxide and
hydrogen peroxide, respectively – prior to, during, and
at resolution of paclitaxel-induced pain. The response of
the antioxidant system during the time-course of
paclitaxel-induced painful neuropathy diﬀers between
DRG and saphenous nerves (purely sensory nerves)
when compared to similar tissues from vehicle-treated
rats. In DRG, there was a signiﬁcant increase in CuZn-
SOD and GPx activity, at day 7 and peak pain, respec-
tively. MnSOD and catalase activity in the DRG were
unaltered throughout the time-course of pain behaviour.
In saphenous nerves from paclitaxel-treated rats at day
7; GPx activity is slightly increased; CuZnSOD activity
signiﬁcantly increased; and MnSOD/catalase activity
unaﬀected. At peak pain, activity of all antioxidant
enzymes was elevated in saphenous nerves, except cata-
lase. At pain resolution, paclitaxel-evoked increases in
antioxidant enzyme activity in saphenous nerves had also
resolved. The increased MnSOD and CuZnSOD activity
in saphenous nerves during paclitaxel-induced pain
observed here, diﬀer to a previous report describing
decreased MnSOD and unchanged CuZnSOD activity at
a similar time-point (Janes et al., 2013). The reason for
this diﬀerence is unclear, perhaps due to diﬀering
techniques.
Electron transport chain activity results in elevation of
superoxide in both the mitochondrial matrix and
mitochondrial intermembrane space. We have found an
upregulation in MnSOD and CuZnSOD activity in
paclitaxel-treated rats. MnSOD is found exclusively in
the mitochondrial matrix. Increased MnSOD activity was
only evident in saphenous nerves at the peak pain time-
point in this study. This indicates that the accumulation
of paclitaxel immediately following injection (Xiao et al.,
2011), is not suﬃcient to directly increase MnSOD activity
in vivo, despite paclitaxel-exposure being shown to
induce MnSOD mRNA expression in vitro (Das et al.,
1998). In comparison, CuZnSOD is typically found in the
cytosol. However, CuZnSOD has been shown to associ-
ate with the outer mitochondrial membrane (Nishiyama
et al., 1996) and to localise to the inner mitochondrial
membrane using metallochaperone CCS1 (copper chap-
erone for SOD) (Okado-Matsumoto and Fridovich, 2001;
Sturtz et al., 2001; Kawamata and Manfredi, 2008).
CCS1 acts at the inner membrane to metallate SOD, pro-
moting CuZnSOD folding and retention in the intermem-
brane space (Sturtz et al., 2001; Bihlmaier et al., 2008;
Kawamata and Manfredi, 2008). Therefore, it is possible
that elevated CuZnSOD activity in paclitaxel-treated rats
occurs in response to increased mitochondrially-located
superoxide. Alternatively, elevated CuZnSOD activity
could indicate increased cytosolic superoxide. Cytosolic
superoxide following paclitaxel may be generated in mito-
chondria. As binding of paclitaxel to b-tubulin will result in
pore opening in the mitochondrial membrane (Varbiroet al., 2001; Carre et al., 2002; Kidd et al., 2002), this pro-
vides a means for mitochondrial superoxide to leak from
the mitochondrial matrix into the cytosol. In addition, pacli-
taxel has also been shown to prevent the closure of the
mitochondrial permeability transition pore (PTP) via stabil-
ising mitochondrial-microtubule interactions, thus poten-
tially maintaining this superoxide leak (Evtodienko et al.,
1996). Such events would ultimately cause swelling and
vacuolisation of mitochondria, as previously observed in
the saphenous nerves and DRG of paclitaxel-treated rats
(Flatters and Bennett, 2006; Barriere et al., 2012). It was
not possible to directly quantify ROS levels in saphenous
nerves due to technical limitations. However, the
increased activity of endogenous antioxidant enzymes in
saphenous nerves at day 7 and peak pain time points
indicate elevated ROS levels – a likely consequence of
atypical mitochondria in saphenous nerves observed at
these time points (Flatters and Bennett, 2006).
Although GPx activity increased at day 7 and peak
pain, catalase activity remained unaltered in DRG and
saphenous nerves. Unaltered catalase activity indicates
a moderate level of hydrogen peroxide manageable via
GPx’s high aﬃnity for the substrate; catalase is known
to function only at high concentrations due to low
hydrogen peroxide aﬃnity, and a decrease in catalase
activity would indicate levels of hydrogen peroxide great
enough to deactivate the catalytic moiety (Altomare
et al., 1974; Halliwell and Gutteridge, 2015). This func-
tional information, in conjunction with GPx’s ability to
locate close to the site of hydrogen peroxide production;
both mitochondrially and cytosolically (Halliwell and
Gutteridge, 2015), demonstrate the important labile nat-
ure of GPx in managing hydrogen peroxide. GPx can pre-
vent activation of peroxisome-bound catalase, supporting
the concept of mitochondrially-derived ROS in paclitaxel-
induced painful neuropathy, with GPx preventing hydro-
gen peroxide-induced cell death. Lack of degeneration
and cell death in the DRG in this low-dose model has
been previously established (Flatters and Bennett, 2006).
A number of changes in antioxidant activity are
concurrent between DRG and saphenous nerves i.e.
CuZnSOD increase at day 7 and GPx increase at peak
pain. Other changes – increases in MnSOD/CuZnSOD
activity at peak pain – are only observed in saphenous
nerves. This implies that ROS elevation in saphenous
nerves is greater and/or prolonged compared to DRG at
peak pain, or that the existing antioxidant activity
capacity in DRG is greater than in saphenous nerves.
Increased SOD activity at day 7 in DRG and saphenous
nerves indicates a subsequent need to manage
elevated hydrogen peroxide; which drives the
upregulation of GPx activity we observe at peak pain
time-point. We suggest there is an inadequate
antioxidant response at day 7, resulting in elevated ROS
prior to pain onset. This causes further mitochondrial
dysfunction (indicated by continued elevated SOD at
peak pain) and/or initiation of signalling cascades that
underlie the coasting phenomenon to peak pain severity
at day 28. Indeed, our recent work has highlighted the
importance of early events in the genesis of this pain
state; as antimycin A (complex III inhibitor) inhibited
N. A. Duggett et al. / Neuroscience 333 (2016) 13–26 25development of paclitaxel-induced pain only when
administered before & during paclitaxel administration
(Griﬃths and Flatters, 2015).
CONCLUSIONS
This is the ﬁrst study to identify in vivo ROS within sensory
neurons in conjunction with the development and
maintenance of paclitaxel-induced painful neuropathy.
Thus linking ROS in peripheral and central axons to the
propagation of paclitaxel-induced pain. The response of
the endogenous antioxidant system appears to be
inadequate and delayed in its onset. We suggest that
this causes excessive ROS, which enhances pain
signalling, leading to the development of persistent pain.
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